Zydus Cadila has received final USFDA approval to market Felbamate tablets, used to treat seizures in people with epilepsy, in the American market. The company will market the drug in the strengths of 400 mg and 600 mg and will manufacture the same at its plant in Ahmedabad.
The company has more than 115 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Company Profile : Cadila Healthcare Ltd
Leave a Reply